A Phase 2 interventional study of PF-06882961 and Placebo in Diabetes and Obesity, sponsored by Pfizer. Completed at 38 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-08.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Diabetes Mellitus by Pfizer — 2 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus · Pfizer.
Among the 35 studies in Diabetes Mellitus by Pfizer, this one is the 17th largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 31st registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,073 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 35 studies in Diabetes Mellitus by Pfizer are open now, in 11 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Brazil, Canada and 8 more countries
Ages 18+
By country, each count listing its studies:
Of the 650 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 89 take children under 18; 182 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 13 · Phase 4 2
First in 2000; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 182 across the 30 interventional studies, 3,720 across the 2 observational. Of the 30 that completed or were terminated, 15 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Diabetes Mellitus by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Diabetes Mellitus by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in non-diabetic adults with obesity
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 120 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID
Drug: PF-06882961
The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 120 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID
Drug: PF-06882961
The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 80 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID
Drug: PF-06882961
The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 80 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID
Drug: PF-06882961
Matching Placebo tablets taken twice a day (BID)
Other: Placebo
The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID
Drug: PF-06882961
The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID
Drug: PF-06882961
PF-68882961 will be provided as tablets twice a day (BID)
Placebo comparator will be provided as tablets twice daily for 12 weeks
Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment. AEs presented below were TEAEs. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE. Assessments of AE intensity were defined as mild (easily tolerated, causing minimal discomfort and not interfering with daily activities), moderate (causing sufficient discomfort and interferes with normal daily activities) and severe (preventing normal daily activities).
Time frame: Baseline through follow-up (Day 112)
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion.
Time frame: Baseline through Visit 10 (Day 91)
Number of Participants With Vital Signs Meeting the Pre-defined Categorical Summarization Criteria
Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP \>=30 mmHg; 5) change from baseline (increase or decrease) in supine DBP \>=20 mmHg.
Time frame: Baseline through Visit 10 (Day 91)
Number of Participants With Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria
ECG assessments included pulse rate (PR), QT, heart rate, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300 msec, or baseline (BL) \>200 msec and \>=25% increase from BL, or BL \<=200 msec and \>=50% increase from BL; QRS interval value \>= 140msec, or \>=50% increase from BL; QTcF value \>450 and \<=480 msec, or \>480 and \<=500 msec, or \>500 msec, or increase from BL\>30 and \<=60 msec, or \>60msec.
Time frame: Baseline through Visit 10 (Day 91)
Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. Participants who responded "yes" to the questions will be counted. Data relevant to the assessment of suicidality were mapped to the Columbia-Classification Algorithm of Suicide Assessment (C-CASA) codes.
Time frame: Week 0, 2, 4, 6, 8, 10, 12, 13-14
Number of Participants With Response to Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The PHQ-9 were completed by participants and reviewed by site staff at the pre-defined time points.
Time frame: Week 0, 2, 4, 6, 8, 10, 12, 13-14.
Change From Baseline (CFB) in Fasting Plasma Glucose at Week 2
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 2
CFB in Fasting Plasma Glucose at Week 4
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 4
CFB in Fasting Plasma Glucose at Week 6
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 6
CFB in Fasting Plasma Glucose at Week 8
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 8
CFB in Fasting Plasma Glucose at Week 10
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 10
CFB in Fasting Plasma Glucose at Week 12
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 12
CFB in Glycolated Hemoglobin A1c (HbA1c) at Week 2
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 2
CFB in Glycolated HbA1c at Week 4
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 4
CFB in Glycolated HbA1c at Week 6
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 6
CFB in Glycolated HbA1c at Week 8
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 8
CFB in Glycolated HbA1c at Week 10
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 10
CFB in Glycolated HbA1c at Week 12
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
Time frame: Baseline, Week 12
CFB in Body Weight at Week 2 (Participants With T2DM)
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
Time frame: Baseline, Week 2
CFB in Body Weight at Week 4 (Participants With T2DM)
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
Time frame: Baseline, Week 4
CFB in Body Weight at Week 6 (Participants With T2DM)
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
Time frame: Baseline, Week 6
CFB in Body Weight at Week 8 (Participants With T2DM)
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
Time frame: Baseline, Week 8
CFB in Body Weight at Week 10 (Participants With T2DM)
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
Time frame: Baseline, Week 10
CFB in Body Weight at Week 12 (Participants With T2DM)
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
Time frame: Baseline, Week 12
CFB in Body Weight at Week 2 (Non-diabetic Participants With Obesity)
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
Time frame: Baseline, Week 2
CFB in Body Weight at Week 4 (Non-diabetic Participants With Obesity)
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
Time frame: Baseline, Week 4
CFB in Body Weight at Week 6 (Non-diabetic Participants With Obesity)
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
Time frame: Baseline, Week 6
CFB in Body Weight at Week 8 (Non-diabetic Participants With Obesity)
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
Time frame: Baseline, Week 8
CFB in Body Weight at Week 10 (Non-diabetic Participants With Obesity)
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
Time frame: Baseline, Week 10
CFB in Body Weight at Week 12 (Non-diabetic Participants With Obesity)
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
Time frame: Baseline, Week 12
Participants were enrolled from 06 January 2021 to 17 November 2021 in the United States.
| Milestone | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|---|---|---|---|---|---|
| Started | 16 | 20 | 22 | 22 | 22 | 21 | 6 | 22 |
| Completed | 13 | 13 | 16 | 13 | 13 | 10 | 5 | 6 |
| Not completed | 3 | 7 | 6 | 9 | 9 | 11 | 1 | 16 |
| Withdrew: Adverse event | 1 | 6 | 4 | 6 | 7 | 8 | 0 | 12 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 | 0 | 3 | 0 | 2 |
| Withdrew: No longer meets eligibility criteria | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 2 | 2 | 0 | 1 | 2 |
| Milestone | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|---|---|---|---|---|---|
| Started | 16 | 20 | 22 | 22 | 22 | 21 | 6 | 22 |
| Completed | 13 | 17 | 18 | 16 | 16 | 14 | 5 | 14 |
| Not completed | 3 | 3 | 4 | 6 | 6 | 7 | 1 | 8 |
| Withdrew: Adverse event | 1 | 1 | 2 | 3 | 4 | 3 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 | 2 | 0 | 0 | 4 | 0 | 3 |
| Withdrew: No longer meets eligibility criteria | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 2 | 2 | 0 | 1 | 2 |
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment. AEs presented below were TEAEs. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE. Assessments of AE intensity were defined as mild (easily tolerated, causing minimal discomfort and not interfering with daily activities), moderate (causing sufficient discomfort and interferes with normal daily activities) and severe (preventing normal daily activities).
| Participants | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|---|---|---|---|---|---|
| All Causality - Mild | 5 | 4 | 10 | 9 | 8 | 10 | 1 | 6 |
| All Causality - Moderate | 3 | 8 | 3 | 5 | 6 | 3 | 3 | 11 |
| All Causality - Severe | 0 | 0 | 1 | 2 | 1 | 1 | 0 | 1 |
| Treatment Related - Mild | 2 | 4 | 8 | 3 | 7 | 9 | 0 | 5 |
| Treatment Related - Moderate | 2 | 4 | 2 | 3 | 7 | 3 | 1 | 11 |
| Treatment Related - Severe | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 1 |
Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion.
| Participants | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | 12 | 16 | 17 | 20 | 17 | 14 | 4 | 9 |
Vital signs abnormality criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP \>=30 mmHg; 5) change from baseline (increase or decrease) in supine DBP \>=20 mmHg.
| Participants | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|---|---|---|---|---|---|
| Supine SBP <90 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine SBP Increase >=30 mmHg | 0 | 0 | 2 | 0 | 4 | 1 | 0 | 0 |
| Supine SBP Decrease >=30 mmHg | 0 | 2 | 1 | 3 | 2 | 1 | 1 | 2 |
| Supine DBP <50 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine DBP Increase >=20 mmHg | 1 | 0 | 2 | 0 | 2 | 1 | 0 | 0 |
| Supine DBP Decrease >=20 mmHg | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Supine Pulse Rate <40 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine Pulse Rate >120 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ECG assessments included pulse rate (PR), QT, heart rate, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300 msec, or baseline (BL) \>200 msec and \>=25% increase from BL, or BL \<=200 msec and \>=50% increase from BL; QRS interval value \>= 140msec, or \>=50% increase from BL; QTcF value \>450 and \<=480 msec, or \>480 and \<=500 msec, or \>500 msec, or increase from BL\>30 and \<=60 msec, or \>60msec.
| Participants | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|---|---|---|---|---|---|
| PR interval >=300 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| %Change in PR interval >=25/50% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QRS interval >=140 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| %Change in QRS interval >=50% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF interval >450 and <=480 msec | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 1 |
| QTcF interval >480 and <=500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| QTcF interval >500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in QTcF interval >30 and <=60 msec | 2 | 0 | 0 | 1 | 3 | 0 | 0 | 0 |
| Change in QTcF interval >60 msec | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
The C-SSRS is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. Participants who responded "yes" to the questions will be counted. Data relevant to the assessment of suicidality were mapped to the Columbia-Classification Algorithm of Suicide Assessment (C-CASA) codes.
| Participants | Placebo (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|---|---|---|---|---|---|
| Week 0 - <1> Completed Suicide | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 0 - <2> Suicide Attempt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 0 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 0 - <4> Suicidal Ideation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 0 - <7> Self-injurious Behavior, No Suicidal Intent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - <1> Completed Suicide | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - <2> Suicide Attempt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - <4> Suicidal Ideation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - <7> Self-injurious Behavior, No Suicidal Intent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - <1> Completed Suicide | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - <2> Suicide Attempt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - <4> Suicidal Ideation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - <7> Self-injurious Behavior, No Suicidal Intent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 - <1> Completed Suicide | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 - <2> Suicide Attempt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 - <4> Suicidal Ideation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 - <7> Self-injurious Behavior, No Suicidal Intent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - <1> Completed Suicide | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - <2> Suicide Attempt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - <4> Suicidal Ideation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - <7> Self-injurious Behavior, No Suicidal Intent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - <1> Completed Suicide | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - <2> Suicide Attempt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - <4> Suicidal Ideation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - <7> Self-injurious Behavior, No Suicidal Intent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - <1> Completed Suicide | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - <2> Suicide Attempt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - <4> Suicidal Ideation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - <7> Self-injurious Behavior, No Suicidal Intent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - <1> Completed Suicide | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - <2> Suicide Attempt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - <3> Preparatory Acts Towards Imminent Suicidal Behavior | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - <4> Suicidal Ideation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - <7> Self-injurious Behavior, No Suicidal Intent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The PHQ-9 were completed by participants and reviewed by site staff at the pre-defined time points.
| Participants | Placebo (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|---|---|---|---|---|---|
| Week 0 - Little Interest/Pleasure in Things - Not At All | 15 | 6 | 16 | 20 | 20 | 20 | 19 | 21 |
| Week 0 - Little Interest/Pleasure in Things - Several Days | 1 | 0 | 3 | 1 | 1 | 1 | 1 | 1 |
| Week 0 - Little Interest/Pleasure in Things - More Than Half the Days | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 |
| Week 0 - Little Interest/Pleasure in Things - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 0 - Feeling Down Depressed or Hopeless - Not At All | 14 | 6 | 19 | 18 | 19 | 22 | 19 | 19 |
| Week 0 - Feeling Down Depressed or Hopeless - Several Days | 2 | 0 | 1 | 3 | 1 | 0 | 2 | 3 |
| Week 0 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Week 0 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 0 - Trouble Falling or Staying Asleep - Not At All | 15 | 5 | 13 | 16 | 17 | 17 | 17 | 15 |
| Week 0 - Trouble Falling or Staying Asleep - Several Days | 1 | 0 | 5 | 4 | 2 | 4 | 2 | 7 |
| Week 0 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 | 1 | 2 | 1 | 2 | 1 | 1 | 0 |
| Week 0 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Week 0 - Feeling Tired or Little Energy - Not At All | 13 | 3 | 13 | 15 | 17 | 16 | 14 | 15 |
| Week 0 - Feeling Tired or Little Energy - Several Days | 3 | 2 | 5 | 4 | 4 | 4 | 6 | 7 |
| Week 0 - Feeling Tired or Little Energy - More Than Half the Days | 0 | 1 | 2 | 2 | 0 | 2 | 1 | 0 |
| Week 0 - Feeling Tired or Little Energy - Nearly Every Day | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Week 0 - Poor Appetite or Overeating - Not At All | 15 | 3 | 13 | 19 | 18 | 19 | 21 | 20 |
| Week 0 - Poor Appetite or Overeating - Several Days | 1 | 2 | 6 | 1 | 3 | 2 | 0 | 1 |
| Week 0 - Poor Appetite or Overeating - More Than Half the Days | 0 | 1 | 1 | 2 | 0 | 1 | 0 | 1 |
| Week 0 - Poor Appetite or Overeating - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 0 - Feeling Bad About Yourself - Not At All | 16 | 6 | 20 | 22 | 20 | 22 | 21 | 21 |
| Week 0 - Feeling Bad About Yourself - Several Days | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Week 0 - Feeling Bad About Yourself - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 0 - Feeling Bad About Yourself - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 0 - Trouble Concentrating on Things - Not At All | 16 | 5 | 16 | 21 | 19 | 20 | 21 | 20 |
| Week 0 - Trouble Concentrating on Things - Several Days | 0 | 1 | 3 | 1 | 1 | 2 | 0 | 2 |
| Week 0 - Trouble Concentrating on Things - More Than Half the Days | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Week 0 - Trouble Concentrating on Things - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 0 - Moving Slowly or Fidgety/Restless - Not At All | 16 | 6 | 19 | 22 | 21 | 21 | 21 | 21 |
| Week 0 - Moving Slowly or Fidgety/Restless - Several Days | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
| Week 0 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 0 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 0 - Thoughts You Be Better Off Dead - Not At All | 16 | 6 | 20 | 22 | 21 | 22 | 21 | 22 |
| Week 0 - Thoughts You Be Better Off Dead - Several Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 0 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 0 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - Little Interest/Pleasure in Things - Not At All | 13 | 5 | 16 | 17 | 21 | 19 | 16 | 18 |
| Week 2 - Little Interest/Pleasure in Things - Several Days | 1 | 1 | 4 | 2 | 0 | 2 | 2 | 1 |
| Week 2 - Little Interest/Pleasure in Things - More Than Half the Days | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Week 2 - Little Interest/Pleasure in Things - Nearly Every Day | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Week 2 - Feeling Down Depressed or Hopeless - Not At All | 12 | 6 | 18 | 20 | 21 | 21 | 17 | 18 |
| Week 2 - Feeling Down Depressed or Hopeless - Several Days | 2 | 0 | 2 | 1 | 0 | 0 | 2 | 2 |
| Week 2 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - Trouble Falling or Staying Asleep - Not At All | 14 | 4 | 14 | 16 | 19 | 17 | 13 | 15 |
| Week 2 - Trouble Falling or Staying Asleep - Several Days | 0 | 1 | 5 | 2 | 2 | 3 | 4 | 5 |
| Week 2 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 |
| Week 2 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 0 |
| Week 2 - Feeling Tired or Little Energy - Not At All | 11 | 3 | 13 | 17 | 18 | 17 | 16 | 14 |
| Week 2 - Feeling Tired or Little Energy - Several Days | 3 | 2 | 6 | 2 | 3 | 3 | 2 | 5 |
| Week 2 - Feeling Tired or Little Energy - More Than Half the Days | 0 | 1 | 0 | 2 | 0 | 1 | 1 | 1 |
| Week 2 - Feeling Tired or Little Energy - Nearly Every Day | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - Poor Appetite or Overeating - Not At All | 12 | 2 | 15 | 15 | 19 | 18 | 17 | 17 |
| Week 2 - Poor Appetite or Overeating - Several Days | 2 | 3 | 4 | 6 | 2 | 2 | 2 | 2 |
| Week 2 - Poor Appetite or Overeating - More Than Half the Days | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Week 2 - Poor Appetite or Overeating - Nearly Every Day | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - Feeling Bad About Yourself - Not At All | 14 | 6 | 18 | 21 | 21 | 20 | 19 | 19 |
| Week 2 - Feeling Bad About Yourself - Several Days | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
| Week 2 - Feeling Bad About Yourself - More Than Half the Days | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - Feeling Bad About Yourself - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - Trouble Concentrating on Things - Not At All | 14 | 5 | 17 | 20 | 20 | 19 | 18 | 18 |
| Week 2 - Trouble Concentrating on Things - Several Days | 0 | 0 | 2 | 1 | 1 | 2 | 1 | 2 |
| Week 2 - Trouble Concentrating on Things - More Than Half the Days | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - Trouble Concentrating on Things - Nearly Every Day | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - Moving Slowly or Fidgety/Restless - Not At All | 14 | 5 | 19 | 20 | 21 | 21 | 18 | 20 |
| Week 2 - Moving Slowly or Fidgety/Restless - Several Days | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Week 2 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - Thoughts You Be Better Off Dead - Not At All | 14 | 6 | 20 | 21 | 21 | 21 | 19 | 20 |
| Week 2 - Thoughts You Be Better Off Dead - Several Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 2 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - Little Interest/Pleasure in Things - Not At All | 12 | 4 | 16 | 20 | 21 | 19 | 18 | 16 |
| Week 4 - Little Interest/Pleasure in Things - Several Days | 2 | 0 | 3 | 0 | 0 | 3 | 1 | 1 |
| Week 4 - Little Interest/Pleasure in Things - More Than Half the Days | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Week 4 - Little Interest/Pleasure in Things - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 -Feeling Down Depressed or Hopeless - Not At All | 13 | 5 | 18 | 18 | 21 | 22 | 18 | 15 |
| Week 4 - Feeling Down Depressed or Hopeless - Several Days | 1 | 0 | 1 | 3 | 0 | 0 | 1 | 2 |
| Week 4 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - Trouble Falling or Staying Asleep - Not At All | 13 | 3 | 11 | 14 | 20 | 18 | 16 | 14 |
| Week 4 - Trouble Falling or Staying Asleep - Several Days | 1 | 1 | 8 | 4 | 1 | 4 | 2 | 3 |
| Week 4 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Week 4 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 4 - Feeling Tired or Little Energy - Not At All | 11 | 2 | 10 | 17 | 18 | 17 | 14 | 9 |
| Week 4 - Feeling Tired or Little Energy - Several Days | 3 | 1 | 8 | 2 | 1 | 5 | 4 | 8 |
| Week 4 - Feeling Tired or Little Energy - More Than Half the Days | 0 | 2 | 1 | 2 | 2 | 0 | 0 | 0 |
| Week 4 - Feeling Tired or Little Energy - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 4 - Poor Appetite or Overeating - Not At All | 11 | 3 | 14 | 18 | 20 | 16 | 16 | 13 |
| Week 4 - Poor Appetite or Overeating - Several Days | 3 | 2 | 3 | 3 | 0 | 3 | 2 | 2 |
| Week 4 - Poor Appetite or Overeating - More Than Half the Days | 0 | 0 | 1 | 0 | 1 | 3 | 1 | 1 |
| Week 4 - Poor Appetite or Overeating - Nearly Every Day | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Week 4 - Feeling Bad About Yourself - Not At All | 14 | 5 | 19 | 21 | 21 | 22 | 18 | 17 |
| Week 4 - Feeling Bad About Yourself - Several Days | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 4 - Feeling Bad About Yourself - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - Feeling Bad About Yourself - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - Trouble Concentrating on Things - Not At All | 13 | 4 | 16 | 20 | 20 | 21 | 19 | 16 |
| Week 4 - Trouble Concentrating on Things - Several Days | 1 | 1 | 3 | 1 | 1 | 1 | 0 | 1 |
| Week 4 - Trouble Concentrating on Things - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - Trouble Concentrating on Things - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - Moving Slowly or Fidgety/Restless - Not At All | 14 | 4 | 18 | 20 | 21 | 21 | 19 | 17 |
| Week 4 - Moving Slowly or Fidgety/Restless - Several Days | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 |
| Week 4 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - Thoughts You Be Better Off Dead - Not At All | 14 | 5 | 19 | 21 | 21 | 22 | 19 | 17 |
| Week 4 - Thoughts You Be Better Off Dead - Several Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 -Little Interest/Pleasure in Things - Not At All | 12 | 4 | 15 | 17 | 19 | 16 | 14 | 14 |
| Week 6 -Little Interest/Pleasure in Things - Several Days | 2 | 1 | 4 | 2 | 0 | 3 | 1 | 1 |
| Week 6 -Little Interest/Pleasure in Things - More Than Half the Days | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Week 6 -Little Interest/Pleasure in Things - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 -Feeling Down Depressed or Hopeless - Not At All | 12 | 5 | 18 | 20 | 18 | 18 | 15 | 13 |
| Week 6 -Feeling Down Depressed or Hopeless - Several Days | 2 | 0 | 1 | 0 | 1 | 1 | 1 | 2 |
| Week 6 -Feeling Down Depressed or Hopeless - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 -Feeling Down Depressed or Hopeless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 -Trouble Falling or Staying Asleep - Not At All | 12 | 4 | 12 | 14 | 16 | 18 | 12 | 10 |
| Week 6 -Trouble Falling or Staying Asleep - Several Days | 1 | 0 | 7 | 6 | 3 | 1 | 3 | 4 |
| Week 6 -Trouble Falling or Staying Asleep - More Than Half the Days | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Week 6 -Trouble Falling or Staying Asleep - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 6 -Feeling Tired or Little Energy - Not At All | 12 | 2 | 11 | 16 | 15 | 15 | 10 | 10 |
| Week 6 -Feeling Tired or Little Energy - Several Days | 2 | 2 | 7 | 3 | 4 | 4 | 5 | 5 |
| Week 6 -Feeling Tired or Little Energy - More Than Half the Days | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 |
| Week 6 -Feeling Tired or Little Energy - Nearly Every Day | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 6 -Poor Appetite or Overeating - Not At All | 12 | 2 | 14 | 14 | 15 | 13 | 9 | 12 |
| Week 6 -Poor Appetite or Overeating - Several Days | 2 | 2 | 4 | 6 | 3 | 3 | 6 | 3 |
| Week 6 -Poor Appetite or Overeating - More Than Half the Days | 0 | 1 | 0 | 0 | 1 | 3 | 1 | 0 |
| Week 6 -Poor Appetite or Overeating - Nearly Every Day | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 6 -Feeling Bad About Yourself - Not At All | 14 | 5 | 18 | 20 | 19 | 19 | 16 | 15 |
| Week 6 -Feeling Bad About Yourself - Several Days | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 6 -Feeling Bad About Yourself - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 -Feeling Bad About Yourself - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 -Trouble Concentrating on Things - Not At All | 13 | 4 | 14 | 19 | 19 | 18 | 16 | 14 |
| Week 6 -Trouble Concentrating on Things - Several Days | 1 | 1 | 5 | 1 | 0 | 1 | 0 | 1 |
| Week 6 -Trouble Concentrating on Things - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 -Trouble Concentrating on Things - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 -Moving Slowly or Fidgety/Restless - Not At All | 14 | 5 | 18 | 20 | 19 | 18 | 16 | 15 |
| Week 6 -Moving Slowly or Fidgety/Restless - Several Days | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Week 6 -Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 -Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 - Thoughts You Be Better Off Dead - Not At All | 14 | 5 | 18 | 20 | 19 | 19 | 16 | 15 |
| Week 6 - Thoughts You Be Better Off Dead - Several Days | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 6 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 6 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Little Interest/Pleasure in Things - Not At All | 13 | 5 | 16 | 16 | 18 | 17 | 15 | 13 |
| Week 8 - Little Interest/Pleasure in Things - Several Days | 1 | 0 | 2 | 2 | 0 | 1 | 1 | 2 |
| Week 8 - Little Interest/Pleasure in Things - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Little Interest/Pleasure in Things - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Feeling Down Depressed or Hopeless - Not At All | 14 | 5 | 18 | 17 | 16 | 18 | 15 | 14 |
| Week 8 - Feeling Down Depressed or Hopeless - Several Days | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 1 |
| Week 8 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Trouble Falling or Staying Asleep - Not At All | 13 | 3 | 12 | 13 | 15 | 17 | 13 | 10 |
| Week 8 - Trouble Falling or Staying Asleep - Several Days | 1 | 1 | 5 | 5 | 3 | 1 | 2 | 5 |
| Week 8 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 8 - Feeling Tired or Little Energy - Not At All | 11 | 3 | 13 | 16 | 16 | 16 | 9 | 10 |
| Week 8 - Feeling Tired or Little Energy - Several Days | 3 | 2 | 4 | 1 | 2 | 2 | 6 | 4 |
| Week 8 - Feeling Tired or Little Energy - More Than Half the Days | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| Week 8 - Feeling Tired or Little Energy - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Poor Appetite or Overeating - Not At All | 11 | 2 | 15 | 13 | 15 | 13 | 9 | 12 |
| Week 8 - Poor Appetite or Overeating - Several Days | 3 | 2 | 3 | 5 | 3 | 3 | 4 | 3 |
| Week 8 - Poor Appetite or Overeating - More Than Half the Days | 0 | 1 | 0 | 0 | 0 | 2 | 2 | 0 |
| Week 8 - Poor Appetite or Overeating - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 8 - Feeling Bad About Yourself - Not At All | 14 | 5 | 18 | 18 | 18 | 18 | 15 | 14 |
| Week 8 - Feeling Bad About Yourself - Several Days | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Week 8 - Feeling Bad About Yourself - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Feeling Bad About Yourself - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Trouble Concentrating on Things - Not At All | 13 | 4 | 14 | 16 | 18 | 17 | 15 | 14 |
| Week 8 - Trouble Concentrating on Things - Several Days | 1 | 1 | 3 | 2 | 0 | 1 | 1 | 1 |
| Week 8 - Trouble Concentrating on Things - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Trouble Concentrating on Things - Nearly Every Day | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Moving Slowly or Fidgety/Restless - Not At All | 14 | 5 | 17 | 18 | 18 | 18 | 16 | 15 |
| Week 8 - Moving Slowly or Fidgety/Restless - Several Days | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Thoughts You Be Better Off Dead - Not At All | 14 | 5 | 18 | 18 | 18 | 18 | 16 | 15 |
| Week 8 - Thoughts You Be Better Off Dead - Several Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 8 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - Little Interest/Pleasure in Things - Not At All | 13 | 5 | 17 | 15 | 16 | 16 | 14 | 13 |
| Week 10 - Little Interest/Pleasure in Things - Several Days | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 2 |
| Week 10 - Little Interest/Pleasure in Things - More Than Half the Days | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Week 10 - Little Interest/Pleasure in Things - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - Feeling Down Depressed or Hopeless - Not At All | 13 | 5 | 18 | 16 | 15 | 17 | 14 | 14 |
| Week 10 - Feeling Down Depressed or Hopeless - Several Days | 1 | 0 | 0 | 2 | 1 | 0 | 1 | 1 |
| Week 10 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - Trouble Falling or Staying Asleep - Not At All | 13 | 3 | 13 | 14 | 14 | 15 | 12 | 10 |
| Week 10 - Trouble Falling or Staying Asleep - Several Days | 1 | 1 | 5 | 3 | 2 | 1 | 2 | 5 |
| Week 10 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| Week 10 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 10 - Feeling Tired or Little Energy - Not At All | 11 | 2 | 11 | 14 | 14 | 13 | 12 | 9 |
| Week 10 - Feeling Tired or Little Energy - Several Days | 3 | 2 | 7 | 3 | 2 | 2 | 2 | 5 |
| Week 10 - Feeling Tired or Little Energy - More Than Half the Days | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 1 |
| Week 10 - Feeling Tired or Little Energy - Nearly Every Day | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Week 10 - Poor Appetite or Overeating - Not At All | 10 | 2 | 15 | 16 | 14 | 11 | 10 | 12 |
| Week 10 - Poor Appetite or Overeating - Several Days | 4 | 3 | 3 | 2 | 1 | 5 | 2 | 3 |
| Week 10 - Poor Appetite or Overeating - More Than Half the Days | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 |
| Week 10 - Poor Appetite or Overeating - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 10 - Feeling Bad About Yourself - Not At All | 14 | 5 | 18 | 18 | 16 | 17 | 14 | 15 |
| Week 10 - Feeling Bad About Yourself - Several Days | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 10 - Feeling Bad About Yourself - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - Feeling Bad About Yourself - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - Trouble Concentrating on Things - Not At All | 13 | 5 | 17 | 17 | 16 | 16 | 15 | 15 |
| Week 10 - Trouble Concentrating on Things - Several Days | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Week 10 - Trouble Concentrating on Things - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - Trouble Concentrating on Things - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - Moving Slowly or Fidgety/Restless - Not At All | 14 | 5 | 17 | 17 | 16 | 16 | 15 | 15 |
| Week 10 - Moving Slowly or Fidgety/Restless - Several Days | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Week 10 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Week 10 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - Thoughts You Be Better Off Dead - Not At All | 14 | 5 | 18 | 18 | 16 | 17 | 15 | 15 |
| Week 10 - Thoughts You Be Better Off Dead - Several Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 10 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Little Interest/Pleasure in Things - Not At All | 11 | 5 | 15 | 14 | 16 | 16 | 13 | 14 |
| Week 12 - Little Interest/Pleasure in Things - Several Days | 2 | 0 | 3 | 2 | 0 | 0 | 1 | 0 |
| Week 12 - Little Interest/Pleasure in Things - More Than Half the Days | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Week 12 - Little Interest/Pleasure in Things - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Feeling Down Depressed or Hopeless - Not At All | 11 | 5 | 18 | 17 | 16 | 16 | 13 | 14 |
| Week 12 - Feeling Down Depressed or Hopeless - Several Days | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Week 12 - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Trouble Falling or Staying Asleep - Not At All | 11 | 3 | 12 | 12 | 15 | 14 | 12 | 9 |
| Week 12 - Trouble Falling or Staying Asleep - Several Days | 2 | 2 | 6 | 5 | 1 | 1 | 1 | 4 |
| Week 12 - Trouble Falling or Staying Asleep - More Than Half the Days | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
| Week 12 - Trouble Falling or Staying Asleep - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 12 - Feeling Tired or Little Energy - Not At All | 10 | 3 | 12 | 14 | 14 | 14 | 11 | 9 |
| Week 12 - Feeling Tired or Little Energy - Several Days | 3 | 2 | 6 | 3 | 2 | 2 | 3 | 5 |
| Week 12 - Feeling Tired or Little Energy - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Feeling Tired or Little Energy - Nearly Every Day | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Week 12 - Poor Appetite or Overeating - Not At All | 10 | 2 | 14 | 13 | 14 | 14 | 9 | 12 |
| Week 12 - Poor Appetite or Overeating - Several Days | 3 | 3 | 3 | 5 | 2 | 2 | 4 | 1 |
| Week 12 - Poor Appetite or Overeating - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Poor Appetite or Overeating - Nearly Every Day | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Week 12 - Feeling Bad About Yourself - Not At All | 13 | 5 | 18 | 18 | 16 | 16 | 13 | 14 |
| Week 12 - Feeling Bad About Yourself - Several Days | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 12 - Feeling Bad About Yourself - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Feeling Bad About Yourself - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Trouble Concentrating on Things - Not At All | 11 | 5 | 17 | 17 | 16 | 16 | 14 | 14 |
| Week 12 - Trouble Concentrating on Things - Several Days | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Trouble Concentrating on Things - More Than Half the Days | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Week 12 - Trouble Concentrating on Things - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Moving Slowly or Fidgety/Restless - Not At All | 12 | 5 | 17 | 18 | 16 | 16 | 14 | 14 |
| Week 12 - Moving Slowly or Fidgety/Restless - Several Days | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Thoughts You Be Better Off Dead - Not At All | 13 | 5 | 18 | 18 | 16 | 16 | 14 | 14 |
| Week 12 - Thoughts You Be Better Off Dead - Several Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Thoughts You Be Better Off Dead - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12 - Thoughts You Be Better Off Dead - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Little Interest/Pleasure in Things - Not At All | 11 | 5 | 14 | 17 | 16 | 17 | 13 | 12 |
| Follow-Up - Little Interest/Pleasure in Things - Several Days | 2 | 0 | 3 | 1 | 0 | 0 | 1 | 1 |
| Follow-Up - Little Interest/Pleasure in Things - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Follow-Up - Little Interest/Pleasure in Things - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Feeling Down Depressed or Hopeless - Not At All | 13 | 5 | 17 | 17 | 16 | 16 | 13 | 12 |
| Follow-Up - Feeling Down Depressed or Hopeless - Several Days | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 2 |
| Follow-Up - Feeling Down Depressed or Hopeless - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Feeling Down Depressed or Hopeless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Trouble Falling or Staying Asleep - Not At All | 12 | 4 | 12 | 13 | 14 | 15 | 12 | 9 |
| Follow-Up - Trouble Falling or Staying Asleep - Several Days | 0 | 1 | 5 | 5 | 2 | 2 | 1 | 4 |
| Follow-Up - Trouble Falling or Staying Asleep - More Than Half the Days | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Trouble Falling or Staying Asleep - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Follow-Up - Feeling Tired or Little Energy - Not At All | 11 | 2 | 11 | 14 | 14 | 17 | 12 | 9 |
| Follow-Up - Feeling Tired or Little Energy - Several Days | 2 | 3 | 5 | 4 | 2 | 0 | 2 | 4 |
| Follow-Up - Feeling Tired or Little Energy - More Than Half the Days | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Follow-Up - Feeling Tired or Little Energy - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Poor Appetite or Overeating - Not At All | 11 | 3 | 13 | 16 | 15 | 16 | 12 | 12 |
| Follow-Up - Poor Appetite or Overeating - Several Days | 2 | 2 | 4 | 2 | 1 | 1 | 2 | 1 |
| Follow-Up - Poor Appetite or Overeating - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Follow-Up - Poor Appetite or Overeating - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Feeling Bad About Yourself - Not At All | 13 | 5 | 17 | 18 | 16 | 17 | 13 | 13 |
| Follow-Up - Feeling Bad About Yourself - Several Days | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Follow-Up - Feeling Bad About Yourself - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Follow-Up - Feeling Bad About Yourself - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Trouble Concentrating on Things - Not At All | 12 | 5 | 17 | 16 | 16 | 17 | 14 | 13 |
| Follow-Up - Trouble Concentrating on Things - Several Days | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 1 |
| Follow-Up - Trouble Concentrating on Things - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Trouble Concentrating on Things - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Moving Slowly or Fidgety/Restless - Not At All | 12 | 5 | 17 | 18 | 16 | 17 | 14 | 14 |
| Follow-Up - Moving Slowly or Fidgety/Restless - Several Days | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Moving Slowly or Fidgety/Restless - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Moving Slowly or Fidgety/Restless - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Thoughts You Be Better Off Dead - Not At All | 13 | 5 | 17 | 18 | 16 | 17 | 14 | 14 |
| Follow-Up - Thoughts You Be Better Off Dead - Several Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Thoughts You Be Better Off Dead - More Than Half the Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up - Thoughts You Be Better Off Dead - Nearly Every Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
| mg/dL | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| Change From Baseline (CFB) in Fasting Plasma Glucose at Week 2 | -5.63 (-19.00 to 7.74) | -3.32 (-14.62 to 7.97) | -23.04 (-34.05 to -12.03) | -36.48 (-47.44 to -25.52) | -39.29 (-50.23 to -28.35) | -25.15 (-36.59 to -13.72) |
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
| mg/dL | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Fasting Plasma Glucose at Week 4 | -13.12 (-26.88 to 0.64) | -16.45 (-28.11 to -4.79) | -32.77 (-43.98 to -21.55) | -45.92 (-57.20 to -34.64) | -48.97 (-60.52 to -37.42) | -41.60 (-53.38 to -29.83) |
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
| mg/dL | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Fasting Plasma Glucose at Week 6 | -3.75 (-19.85 to 12.35) | -29.33 (-43.35 to -15.31) | -36.70 (-50.13 to -23.27) | -43.82 (-57.90 to -29.75) | -49.22 (-63.14 to -35.31) | -37.38 (-51.77 to -22.99) |
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
| mg/dL | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Fasting Plasma Glucose at Week 8 | -5.90 (-20.83 to 9.04) | -33.69 (-47.42 to -19.96) | -31.57 (-44.56 to -18.58) | -52.84 (-66.55 to -39.13) | -39.69 (-53.63 to -25.75) | -48.02 (-62.47 to -33.57) |
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
| mg/dL | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Fasting Plasma Glucose at Week 10 | -23.39 (-39.07 to -7.71) | -36.24 (-51.69 to -20.78) | -38.21 (-52.17 to -24.26) | -57.36 (-72.43 to -42.29) | -22.08 (-36.88 to -7.29) | -37.81 (-53.52 to -22.11) |
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
| mg/dL | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Fasting Plasma Glucose at Week 12 | -13.09 (-29.75 to 3.57) | -41.74 (-58.49 to -25.00) | -40.41 (-55.25 to -25.57) | -53.94 (-70.26 to -37.63) | -23.34 (-39.52 to -7.17) | -37.48 (-55.27 to -19.69) |
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
| Percentage | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Glycolated Hemoglobin A1c (HbA1c) at Week 2 | -0.03 (-0.20 to 0.14) | -0.12 (-0.26 to 0.02) | -0.29 (-0.43 to -0.15) | -0.37 (-0.51 to -0.24) | -0.35 (-0.49 to -0.21) | -0.20 (-0.34 to -0.05) |
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
| Percentage | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Glycolated HbA1c at Week 4 | -0.22 (-0.45 to 0.00) | -0.33 (-0.52 to -0.14) | -0.59 (-0.77 to -0.41) | -0.81 (-1.00 to -0.63) | -0.75 (-0.94 to -0.56) | -0.58 (-0.78 to -0.39) |
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
| Percentage | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Glycolated HbA1c at Week 6 | -0.26 (-0.56 to 0.04) | -0.49 (-0.75 to -0.24) | -0.92 (-1.16 to -0.67) | -1.11 (-1.36 to -0.86) | -0.97 (-1.22 to -0.72) | -0.93 (-1.19 to -0.68) |
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
| Percentage | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Glycolated HbA1c at Week 8 | -0.27 (-0.60 to 0.05) | -0.71 (-0.99 to -0.43) | -1.14 (-1.41 to -0.88) | -1.38 (-1.65 to -1.10) | -1.20 (-1.48 to -0.92) | -1.18 (-1.47 to -0.89) |
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
| Percentage | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Glycolated HbA1c at Week 10 | -0.32 (-0.69 to 0.05) | -1.00 (-1.33 to -0.67) | -1.26 (-1.57 to -0.95) | -1.48 (-1.81 to -1.16) | -1.22 (-1.55 to -0.89) | -1.36 (-1.70 to -1.03) |
Baseline was defined as the result closest prior to dosing at Day1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points.
| Percentage | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Glycolated HbA1c at Week 12 | -0.32 (-0.73 to 0.10) | -1.07 (-1.45 to -0.70) | -1.32 (-1.67 to -0.97) | -1.56 (-1.94 to -1.19) | -1.04 (-1.42 to -0.67) | -1.57 (-1.96 to -1.18) |
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
| kg | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Body Weight at Week 2 (Participants With T2DM) | -0.14 (-0.72 to 0.44) | -0.40 (-0.89 to 0.08) | -0.22 (-0.70 to 0.26) | -0.46 (-0.94 to 0.02) | -0.63 (-1.11 to -0.16) | -0.21 (-0.72 to 0.30) |
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
| kg | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Body Weight at Week 4 (Participants With T2DM) | -0.46 (-1.40 to 0.47) | -1.23 (-2.03 to -0.44) | -0.34 (-1.11 to 0.43) | -1.58 (-2.35 to -0.81) | -1.47 (-2.25 to -0.70) | -0.41 (-1.23 to 0.41) |
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
| kg | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Body Weight at Week 6 (Participants With T2DM) | -0.38 (-1.42 to 0.66) | -1.86 (-2.77 to -0.95) | -0.65 (-1.52 to 0.23) | -2.74 (-3.65 to -1.83) | -2.23 (-3.13 to -1.33) | -1.16 (-2.10 to -0.21) |
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
| kg | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Body Weight at Week 8 (Participants With T2DM) | -0.36 (-1.51 to 0.80) | -2.52 (-3.55 to -1.48) | -1.08 (-2.07 to -0.09) | -3.82 (-4.86 to -2.79) | -2.41 (-3.43 to -1.38) | -3.32 (-4.42 to -2.23) |
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
| kg | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Body Weight at Week 10 (Participants With T2DM) | -0.67 (-1.96 to 0.61) | -3.14 (-4.34 to -1.93) | -1.71 (-2.83 to -0.58) | -4.95 (-6.15 to -3.75) | -3.35 (-4.53 to -2.18) | -4.38 (-5.64 to -3.12) |
Baseline was defined as the average of a duplicate measurement closest prior to dosing at Day 1. The MMRM model included treatment, time, strata (male versus female) and treatment-by-time interaction as fixed effects, baseline as a covariate and the baseline-by-time interaction with time fitted as a repeated effect and participant as a random effect. An unstructured covariance matrix was used to estimate the variances and covariance within participant across time points. Average of the duplicate measurements (where applicable) was used in analyses.
| kg | Placebo (T2DM) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) |
|---|---|---|---|---|---|---|
| CFB in Body Weight at Week 12 (Participants With T2DM) | -0.42 (-1.87 to 1.03) | -3.64 (-5.03 to -2.24) | -1.93 (-3.22 to -0.64) | -5.38 (-6.77 to -3.98) | -2.93 (-4.29 to -1.56) | -5.37 (-6.86 to -3.88) |
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
| kg | Placebo (Non-diabetic Obesity) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|
| CFB in Body Weight at Week 2 (Non-diabetic Participants With Obesity) | 0.23 (-0.81 to 1.26) | -0.73 (-1.34 to -0.13) |
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
| kg | Placebo (Non-diabetic Obesity) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|
| CFB in Body Weight at Week 4 (Non-diabetic Participants With Obesity) | 0.09 (-1.21 to 1.40) | -1.50 (-2.25 to -0.74) |
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
| kg | Placebo (Non-diabetic Obesity) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|
| CFB in Body Weight at Week 6 (Non-diabetic Participants With Obesity) | -0.10 (-2.28 to 2.08) | -1.59 (-2.86 to -0.33) |
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
| kg | Placebo (Non-diabetic Obesity) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|
| CFB in Body Weight at Week 8 (Non-diabetic Participants With Obesity) | 0.26 (-2.57 to 3.09) | -2.36 (-4.08 to -0.65) |
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
| kg | Placebo (Non-diabetic Obesity) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|
| CFB in Body Weight at Week 10 (Non-diabetic Participants With Obesity) | -0.40 (-3.17 to 2.37) | -3.47 (-5.21 to -1.73) |
Body weight were measured in duplicate as indicated. The second weight measurement were obtained at least 1-2 minutes apart from the first weight measurement. Weight were recorded using a calibrated scale (with the same scale used if possible for the duration of the study) reporting weight in kilograms (kg), and accuracy to the nearest 0.1 kg; ie, the device distinguished a difference between 68.4 kg vs 68.3 kg. The scale was placed on a stable, flat surface. Weight measurement was taken under the following conditions: participant is in a fasted state; after void of urine; after removal of shoes, bulky layers of clothing and jackets so that only light clothing remained; while remaining was during the measurement.
| kg | Placebo (Non-diabetic Obesity) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|
| CFB in Body Weight at Week 12 (Non-diabetic Participants With Obesity) | -0.11 (-3.93 to 3.72) | -3.85 (-6.25 to -1.44) |
Collected over Baseline through follow-up (Day 112-119).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (T2DM) | 0/16 (0%) | 0/16 (0%) | 8/16 (50%) |
| Placebo (Non-diabetic Obesity) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| PF-06882961 80 mg BID Low, Slow (T2DM) | 0/20 (0%) | 0/20 (0%) | 11/20 (55%) |
| PF-06882961 80 mg BID High, Slow (T2DM) | 0/22 (0%) | 0/22 (0%) | 13/22 (59.1%) |
| PF-06882961 120 mg BID Low, Fast (T2DM) | 0/22 (0%) | 0/22 (0%) | 14/22 (63.6%) |
| PF-06882961 120 mg BID High, Fast (T2DM) | 0/22 (0%) | 0/22 (0%) | 14/22 (63.6%) |
| PF-06882961 200 mg BID (T2DM) | 0/21 (0%) | 0/21 (0%) | 14/21 (66.7%) |
| PF-06882961 200 mg BID (Non-diabetic Obesity) | 0/22 (0%) | 0/22 (0%) | 18/22 (81.8%) |
| Event | Placebo (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | PF-06882961 200 mg BID (Non-diabetic Obesity) |
|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/16 | 0/6 | 4/20 | 5/22 | 6/22 | 8/22 | 10/21 | 13/22 |
| VomitingGastrointestinal disorders | 2/16 | 0/6 | 5/20 | 4/22 | 6/22 | 9/22 | 6/21 | 10/22 |
| DiarrhoeaGastrointestinal disorders | 2/16 | 0/6 | 2/20 | 1/22 | 5/22 | 5/22 | 1/21 | 1/22 |
| DyspepsiaGastrointestinal disorders | 0/16 | 0/6 | 1/20 | 1/22 | 2/22 | 5/22 | 1/21 | 1/22 |
| Decreased appetiteMetabolism and nutrition disorders | 1/16 | 0/6 | 1/20 | 2/22 | 4/22 | 1/22 | 4/21 | 0/22 |
| DizzinessNervous system disorders | 1/16 | 0/6 | 2/20 | 1/22 | 2/22 | 2/22 | 0/21 | 4/22 |
| PalpitationsCardiac disorders | 0/16 | 1/6 | 0/20 | 0/22 | 2/22 | 0/22 | 0/21 | 0/22 |
| GastroenteritisInfections and infestations | 0/16 | 1/6 | 0/20 | 0/22 | 0/22 | 0/22 | 0/21 | 0/22 |
| Gastroenteritis viralInfections and infestations | 0/16 | 1/6 | 0/20 | 0/22 | 0/22 | 0/22 | 0/21 | 0/22 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/16 | 1/6 | 0/20 | 0/22 | 0/22 | 0/22 | 0/21 | 0/22 |
A total of 151 participants were assigned to the treatment and treated with danuglipron or placebo.
| Age, Continuous(Years) | Placebo (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | PF-06882961 200 mg BID (Non-diabetic Obesity) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean (SD) | 53.9 ± 9.10 | 49.5 ± 5.79 | 59.5 ± 9.55 | 60.9 ± 8.69 | 58.3 ± 7.11 | 57.2 ± 11.8 | 59 ± 9.31 | 48.5 ± 13.12 | 56.5 ± 10.55 |
| Age, Continuous(Years) | Placebo (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | PF-06882961 200 mg BID (Non-diabetic Obesity) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Median | 53.0 (39 to 69) | 49.0 (42 to 59) | 60.5 (34 to 72) | 61.5 (46 to 74) | 58.5 (41 to 71) | 60.0 (32 to 75) | 59.0 (44 to 75) | 52.0 (21 to 69) | 58.0 (21 to 75) |
| Age, Customized(Participants) | Placebo (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | PF-06882961 200 mg BID (Non-diabetic Obesity) | Total |
|---|---|---|---|---|---|---|---|---|---|
| <18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18-44 | 2 | 1 | 1 | 0 | 1 | 3 | 1 | 7 | 16 |
| 45-64 | 12 | 5 | 12 | 13 | 18 | 12 | 14 | 13 | 99 |
| >=65 | 2 | 0 | 7 | 9 | 3 | 7 | 6 | 2 | 36 |
| Sex: Female, Male(Participants) | Placebo (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | PF-06882961 200 mg BID (Non-diabetic Obesity) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 8 | 4 | 10 | 10 | 10 | 10 | 10 | 16 | 78 |
| Male | 8 | 2 | 10 | 12 | 12 | 12 | 11 | 6 | 73 |
| Race/Ethnicity, Customized(Participants) | Placebo (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | PF-06882961 200 mg BID (Non-diabetic Obesity) | Total |
|---|---|---|---|---|---|---|---|---|---|
| White | 12 | 6 | 17 | 19 | 19 | 17 | 17 | 18 | 125 |
| Black or African American | 4 | 0 | 3 | 2 | 2 | 5 | 3 | 4 | 23 |
| Asian | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Not reported | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo (T2DM) | Placebo (Non-diabetic Obesity) | PF-06882961 80 mg BID Low, Slow (T2DM) | PF-06882961 80 mg BID High, Slow (T2DM) | PF-06882961 120 mg BID Low, Fast (T2DM) | PF-06882961 120 mg BID High, Fast (T2DM) | PF-06882961 200 mg BID (T2DM) | PF-06882961 200 mg BID (Non-diabetic Obesity) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 3 | 12 | 11 | 9 | 11 | 15 | 13 | 83 |
| Not Hispanic or Latino | 7 | 3 | 8 | 11 | 13 | 11 | 6 | 9 | 68 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jan 2021 to primary completion in Nov 2021, 10 months.
Results were first posted in Dec 2022, 1 year after primary completion.
Of 65 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 10 months is below that.
Counting every sponsor, half of 147 studies reached it within 27 months; a quarter within 12 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Danuglipron